FTV

TentativeAI MemoPost-earnings T+3

Fortive

As of 2026-08-03/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-03 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 results and guidance raise support near-term reassessment • 2026-07-29

Base target: $62 / p=50% prob

Biggest risk

The bear case centers on limited evidence of broad-based margin improvement because Advanced Healthcare Solutions margin weakened, alongside higher long-term debt and a negative post-print relative-performance signal. A bounded analyst check found no post-earnings target, rating, or estimate revision in the available evidence; pre-print analyst data should not be treated as confirmation.

Invalidation

Break below $56 or thesis failure.

What would change my mind?

The bull case is supported by accelerating core growth, strong adjusted EPS and cash-flow growth, higher FY2026 guidance, margin expansion in Intelligent Operating Solutions, and sustained repurchases. [#SEC-8K-2026-07-29]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-03

Base target

$62

p=50%

Bull target

$66

p=30%

Bear target

$56

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Advanced Healthcare Solutions margin follow-through
Fortive Accelerated execution and capital returns
The bull case is supported by accelerating core growth, strong adjusted EPS and cash-flow growth, higher FY2026 guidance, margin expansion in Intelligent Operating Solutions, and sustained repurchases.

BearKey bullets

Advanced Healthcare Solutions adjusted EBITDA margin declined 80 basis points year over year in Q2.
[#SEC-8K-2026-07-29]
FY2026 guidance depends on continued execution of the Fortive Accelerated strategy, innovation and commercial initiatives, and recurring-customer-value investments.

WatchKey bullets

Q2 results and guidance raise support near-term reassessment

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $62 (p=50%)

Target spread vs base: +5% / -10%

Scenario probabilities

Bull Target: $66 (p=30%)Base Target: $62 (p=50%)Bear Target: $56 (p=20%)

Commentary

The company-source evidence is concrete and constructive: Fortive raised guidance and reported strong Q2 growth, margins, cash flow, and buybacks. Market reaction was less supportive: the packet's July 29 MarketWatch headline reported relative underperformance versus competitors, while the available RankAlpha anchor was $59.21 on July 31. No exact event-day return or causal attribution is available, and no post-print analyst revision evidence was found. This remains a constructive but monitoring-style view.

As of 2026-08-03 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Advanced Healthcare Solutions margin follow-through
Fortive Accelerated execution and capital returns

Scenarios

Bull Target (Scenario probability)

$66 / p=30% prob

Base Target (Scenario probability)

$62 / p=50% prob

Bear Target (Scenario probability)

$56 / p=20% prob

Analysis 2026-08-03 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-07-29
Q2 results and guidance raise support near-term reassessment
Fortive reported Q2 revenue growth of 7.9% reported and 6.7% core, adjusted EPS growth of 28.5%, adjusted EBITDA growth of 12%, and raised FY2026 adjusted EPS guidance to $2.95-$3.05 from $2.90-$3.00. The release also cited $271 million of quarterly free cash flow and approximately $200 million of buybacks. [#SEC-8K-2026-07-29]
Prob 100.00% • Move 3.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Advanced Healthcare Solutions margin follow-through
2026-08-14
Near-term sentiment may remain mixed if Advanced Healthcare Solutions margin softness persists: Q2 revenue grew 5.3% core, but adjusted EBITDA margin declined 80 basis points year over year, versus a 230-basis-point operating-margin expansion in Intelligent Operating Solutions. [#SEC-8K-2026-07-29]
Prob 35% • Move -5% • Priced-in 45%

Long-term Catalysts

Months to a year

Fortive Accelerated execution and capital returns
2026-12-31
Management cited early evidence that innovation acceleration, commercial acceleration, recurring customer value, and FBS Amplified are improving growth and earnings. Buybacks totaled approximately $2 billion over the last four quarters. [#SEC-8K-2026-07-29]
Prob 60% • Move 10% • Priced-in 45%

Risks

Advanced Healthcare Solutions adjusted EBITDA margin declined 80 basis points year over year in Q2. [#SEC-8K-2026-07-29]
FY2026 guidance depends on continued execution of the Fortive Accelerated strategy, innovation and commercial initiatives, and recurring-customer-value investments. [#SEC-8K-2026-07-29]
Long-term debt was $3.51 billion at July 3, 2026 versus $2.31 billion at December 31, 2025, while cash was $374 million. [#SEC-8K-2026-07-29]
No post-earnings analyst revisions, target changes, or estimate updates were found in the available evidence; missing revision data is not positive evidence.
The release identifies macro cyclicality, tariffs and trade restrictions, supply-chain constraints, competition, execution, acquisition integration, leverage, and regulatory risks. [#SEC-8K-2026-07-29]

Peers

Symbol	Summary
APG	Same-sector, similar-market-cap comparator for industrial growth and execution context; business mix is not identical.
IEX	Same-sector, similar-market-cap comparator with useful industrial instrumentation and margin context; peer overlap is partial.
ITT	Same-sector, similar-market-cap industrial comparator; useful for relative valuation and execution monitoring, but not a close business clone.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-03

Loading AI feed…

Symbol

Summary

APG

Same-sector, similar-market-cap comparator for industrial growth and execution context; business mix is not identical.

IEX

Same-sector, similar-market-cap comparator with useful industrial instrumentation and margin context; peer overlap is partial.

ITT

Same-sector, similar-market-cap industrial comparator; useful for relative valuation and execution monitoring, but not a close business clone.